Dor BioPharma and Steward Cross Sign Collaborative Agreement
Dor BioPharma has entered into collaboration with Steward Cross, a specialty pharmaceutical company based in Singapore, under which Steward Cross will act as Dor’s sponsor with regard to the administration of a Named Patient Access Program for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in Singapore and Malaysia.
The Named Patient Access Program (NPAP) is a compassionate use drug supply program administered by the Health Sciences Authority (HSA) of Singapore and Drug Control Authority (DCA) of Malaysia under which medical practitioners can legally supply investigational drugs to their patients who qualify.
Under this program, investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the HSA and DCA.
Steward Cross and Dor will share revenues generated by sales of orBec through the NPAP. Dor will manufacture and supply orBec to Steward Cross, while Steward Cross will be responsible for all distribution costs in Singapore and Malaysia.
Christopher Schaber, president and CEO of Dor, said: “We are pleased with the interest that Singaporean transplant physicians have expressed in orBec and are looking forward to working closely with Steward Cross to administer this important program.”